Nuvaxovid market report sees booster demand and variant targeting driving growth

The Business Research Company says the Nuvaxovid vaccine market is set to keep evolving through 2035 as booster demand, variant-focused shots and broader vaccine coverage shape demand. North America led the market in 2025, while the report highlights growing interest in protein-based and non-mRNA COVID-19 vaccines.

Why it matters: - The Nuvaxovid market is tied to ongoing COVID-19 vaccination needs, especially booster demand and efforts to prepare for future variants. - Growth in this market also reflects broader demand for vaccines as infectious diseases continue to rise worldwide. - A more diverse vaccine mix matters for governments and health systems that want options beyond mRNA products.

What happened: - The Business Research Company published its Nuvaxovid Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 9, 2026. - The report says the Nuvaxovid vaccine market expanded during the pandemic because of emergency use authorizations, mass immunization programs, higher public health spending and faster vaccine production. - The report forecasts continued market support from 2026 to 2030 through booster shots, vaccines tailored to emerging variants, wider global coverage and pandemic-readiness planning. - Download a free sample of the Nuvaxovid market report - View the full Nuvaxovid market report

The details: - Nuvaxovid is a protein-based COVID-19 vaccine. - The vaccine uses recombinant spike proteins from SARS-CoV-2 and the Matrix-M adjuvant to boost immune response. - Nuvaxovid is given in two doses. - The vaccine has been authorized in several countries for people ages 12 and older. - The report identifies rising infectious disease prevalence as a key market driver. - The report links that rise to international travel, urbanization, climate shifts, antimicrobial resistance and new pathogens. - The report says Nuvaxovid helps prevent COVID-19 and reduce transmission. - The report cites UK Office for National Statistics data showing 2.66% of England’s population tested positive for COVID-19 in one week in March 2023. - The same data showed rising infection rates in Wales, Scotland and Northern Ireland, along with higher hospital admissions and deaths. - Growing vaccine demand is another major driver in the report. - The report points to stronger public awareness, vaccine technology advances and a greater focus on preventive health as demand factors. - The report says Nuvaxovid targets new COVID-19 variants and supports global immunization campaigns. - The U.S. Centers for Disease Control and Prevention reported in November 2024 that by October 2024, 13.7% of U.S. adults 18 and older had received the 2024-25 COVID-19 vaccine. - The CDC also reported that 24.5% of U.S. adults had received a flu shot, with the highest vaccination rates among people 65 and older. - North America held the largest share of the Nuvaxovid market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspot infographics, and updated technology and trend analysis.

Between the lines: - The report frames Nuvaxovid as part of a post-pandemic vaccine market that is shifting from emergency response to ongoing maintenance, variant adaptation and broader portfolio management. - Its emphasis on non-mRNA vaccines suggests there is still commercial and policy room for alternative platforms. - The regional emphasis on North America signals where current demand is strongest, even as the report flags global growth opportunities.

What's next: - The report expects demand to continue through 2030 as booster uptake, variant updates and broader vaccine adoption shape the market. - The market is also likely to be influenced by cold-chain improvements, stronger safety monitoring and further development of protein-based vaccine strategies. - The Business Research Company says its updated 2026 reports will continue to include expanded strategic intelligence and analysis tools.

The bottom line: - Nuvaxovid is positioned as a durable player in a vaccine market moving beyond crisis response and toward long-term COVID-19 management.